{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:07:47Z","timestamp":1789992467531,"version":"4.0.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Apparent diffusion coefficient (ADC) derived from diffusion-weighted imaging (DWI) has been proposed as a quantitative biomarker of prostate cancer aggressiveness, and an inverse relationship between ADC and Gleason score has been reported across numerous single-marker studies and meta-analyses. However, most prior work has compared ADC with serum PSA alone, without accounting for PSA density (PSAD) or potential confounders such as age and prostate volume, and without formally testing \u2014 using multivariable regression and receiver operating characteristic (ROC) analysis \u2014 whether ADC provides incremental diagnostic value beyond PSA-based parameters. Whether the ADC\u2013grade relationship persists after such adjustment, and whether combining ADC with PSA and PSAD meaningfully improves discrimination, remains inconsistently characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether minimum apparent diffusion coefficient (ADC) values are associated with pathological International Society of Urological Pathology (ISUP) Grade Group, and to compare the diagnostic performance of ADC with that of serum PSA and PSA density (PSAD), in patients with histologically confirmed prostate cancer undergoing radical prostatectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study of 192 patients undergoing multiparametric MRI (mpMRI), biopsy, and radical prostatectomy was performed. Minimum ADC values were correlated with the final pathological ISUP Grade Group, serum PSA, PSA density, age, and prostate volume.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Minimum ADC showed a significant inverse correlation with ISUP Grade Group (Spearman\u2019s \u03c1 = \u22120.355; 95% CI, \u22120.473 to \u22120.218; p &amp;lt; 0.001), whereas neither PSA (\u03c1 = 0.012; p = 0.864) nor PSAD (\u03c1 = 0.040; p = 0.578) showed a significant monotonic relationship. On multivariable ordinal logistic regression, minimum ADC remained independently associated with higher ISUP Grade Group after adjustment for age, PSA or PSAD, and prostate volume (OR\u00a0=\u00a00.995 per 1 \u00d7 10\n                      <jats:sup>\u22126<\/jats:sup>\n                      mm\u00b2\/s increase; p &amp;lt; 0.001 in both models), while age, PSA, PSAD, and prostate volume were not independently significant. Minimum ADC discriminated ISUP Grade Group 1 from \u22652 with an AUC of 0.959 (95% CI, 0.923\u20130.988), substantially outperforming PSA (AUC\u00a0=\u00a00.586) and PSAD (AUC\u00a0=\u00a00.562). Combined models incorporating ADC with PSA and\/or PSAD did not significantly improve discrimination over ADC alone (DeLong\u2019s test, all p \u2265 0.10).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this radical prostatectomy cohort, minimum ADC was inversely and independently associated with pathological ISUP Grade Group, whereas serum PSA and PSAD were not. ADC substantially outperformed PSA-based markers for discriminating low- from higher-grade disease, although combining ADC with PSA-based parameters provided no significant incremental benefit. These findings support ADC as a promising quantitative imaging biomarker of tumor grade; however, given the retrospective, single-center, surgically selected design and the small number of ISUP Grade Group 1 cases, prospective multicenter validation is required before ADC-based thresholds can be recommended for active surveillance or biopsy decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1905995","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:16:28Z","timestamp":1789989388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimum ADC outperforms PSA and PSA density for predicting ISUP grade group in prostate cancer: a retrospective study of 192 patients undergoing radical prostatectomy"],"prefix":"10.3389","volume":"16","author":[{"given":"Katarzyna","family":"Skrobisz","sequence":"first","affiliation":[{"name":"Department of Radiology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Bernard","sequence":"additional","affiliation":[{"name":"2nd Department of Radiology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Bromirski","sequence":"additional","affiliation":[{"name":"2nd Department of Radiology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Nowak","sequence":"additional","affiliation":[{"name":"2nd Department of Radiology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Po\u0142om","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Pie\u0144kowska","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.01.043","article-title":"Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer","volume":"74","author":"Mahal","year":"2018","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.euo.2023.08.002","article-title":"Diagnostic performance of prostate-specific antigen density for detecting clinically significant prostate cancer in the era of magnetic resonance imaging: a systematic review and meta-analysis","volume":"7","author":"Wang","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.09.001","article-title":"Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7\u201310 prostate cancer in biopsy-na\u00efve men","volume":"2","author":"Boesen","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"B9","article-title":"Classification of prostatic carcinomas","volume":"50","author":"Gleason","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.11091409","article-title":"Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer","volume":"259","author":"Hambrock","year":"2011","journal-title":"Radiology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.4441","article-title":"Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade","volume":"196","author":"Verma","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13130973","article-title":"Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient","volume":"271","author":"Donati","year":"2014","journal-title":"Radiology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015142414","article-title":"Changes in epithelium, stroma, and lumen space correlate more strongly with Gleason pattern and are stronger predictors of prostate ADC changes than cellularity metrics","volume":"277","author":"Chatterjee","year":"2015","journal-title":"Radiology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.12.006","article-title":"Correlations between apparent diffusion coefficient and Gleason score in prostate cancer: a systematic review","volume":"3","author":"Surov","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12885-020-06942-x","article-title":"Discrimination between clinically significant and insignificant prostate cancer with apparent diffusion coefficient: a systematic review and meta-analysis","volume":"20","author":"Meyer","year":"2020","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1079040","article-title":"Correlation between ADC, ADC ratio, and Gleason Grade Group in prostate cancer patients undergoing radical prostatectomy: retrospective multicenter study with different MRI scanners","volume":"13","author":"Bengtsson","year":"2023","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13091378","article-title":"Quantitative ADC: an additional tool in the evaluation of prostate cancer","volume":"13","author":"Lucarelli","year":"2023","journal-title":"J Pers Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215183","article-title":"Quantitative evaluation of apparent diffusion coefficient values, ISUP grades and prostate-specific antigen density values of potentially Malignant PI-RADS lesions","volume":"15","author":"Spadarotto","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.19.21365","article-title":"Apparent diffusion coefficient (ADC) ratio versus conventional ADC for detecting clinically significant prostate cancer with 3-T MRI","volume":"213","author":"Bajgiran","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.010","article-title":"Nine-year follow-up for a study of diffusion-weighted magnetic resonance imaging in a prospective prostate cancer active surveillance cohort","volume":"69","author":"Henderson","year":"2016","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.011","article-title":"Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations","volume":"71","author":"Moore","year":"2017","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer","volume":"86","author":"Englman","year":"2024","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.050","article-title":"Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review","volume":"67","author":"Schoots","year":"2015","journal-title":"Eur Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4258","article-title":"Magnetic resonance imaging, clinical, and biopsy findings in suspected prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Haj-Mirzaian","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.11.055","article-title":"Serial magnetic resonance imaging in active surveillance of prostate cancer: incremental value","volume":"195","author":"Felker","year":"2016","journal-title":"J Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07336-0","article-title":"MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance","volume":"31","author":"Caglic","year":"2021","journal-title":"Eur Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-019-06557-2","article-title":"Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study","volume":"30","author":"Giganti","year":"2020","journal-title":"Eur Radiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1905995\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:16:29Z","timestamp":1789989389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1905995\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1905995"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1905995","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1905995"}}